Information:
Error:
ID
20995
Description
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]; ODM derived from: https://clinicaltrials.gov/show/NCT00841568
Link
https://clinicaltrials.gov/show/NCT00841568
Keywords
Versions (1)
- 4/2/17 4/2/17 -
Uploaded on
April 2, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Autosomal Dominant Polycystic Kidney Disease NCT00841568
Eligibility Autosomal Dominant Polycystic Kidney Disease NCT00841568
- StudyEvent: Eligibility
Similar models
Eligibility Autosomal Dominant Polycystic Kidney Disease NCT00841568
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
preceding study
Item
patients who completed 5-day repeated administrations and the follow-up observation in the preceding study (156-04-001)
boolean
C2348568 (UMLS CUI [1])
preceding study administration safety confirmed
Item
patients in whom the safety of repeated administration was confirmed based on the investigator's reports from the preceding study (156-04-001)
boolean
C2348568 (UMLS CUI [1,1])
C1533734 (UMLS CUI [1,2])
C0036043 (UMLS CUI [1,3])
C1533734 (UMLS CUI [1,2])
C0036043 (UMLS CUI [1,3])
serum creatinine
Item
patients with serum creatinine concentration of 2.5 mg/dl or higher at the screening examination
boolean
C0201976 (UMLS CUI [1])
complication
Item
patients with any of the following complications
boolean
C0009566 (UMLS CUI [1])
uncontrolled hypertension
Item
uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
cardiovascular or hepatic disease
Item
serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)"
boolean
C0007222 (UMLS CUI [1])
C0023895 (UMLS CUI [2])
C0023895 (UMLS CUI [2])
complications, medical history
Item
patients with any of the following complications or history thereof
boolean
C0009566 (UMLS CUI [1])
C0262926 (UMLS CUI [2])
C0262926 (UMLS CUI [2])
drug hypersensitivity
Item
clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)
boolean
C0013182 (UMLS CUI [1])
informed consent, mental disorder
Item
inability to personally give consent due to a mental disease "
boolean
C0021430 (UMLS CUI [1,1])
C0004936 (UMLS CUI [1,2])
C0004936 (UMLS CUI [1,2])
systolic blood pressure
Item
patients with sbp (in sitting position) <90 mm hg (at screening examination)
boolean
C0871470 (UMLS CUI [1])
bleeding tendency
Item
patients with history of massive bleeding or bleeding tendency
boolean
C1458140 (UMLS CUI [1])
drug or alcohol abuse
Item
patients with a history of drug or alcohol abuse within 6 months prior to the screening examination
boolean
C0038586 (UMLS CUI [1])
pregnancy, lactation, child bearing potential
Item
pregnant women, lactating women, or women who may become or plan to become pregnant
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C1960468 (UMLS CUI [3])
C0006147 (UMLS CUI [2])
C1960468 (UMLS CUI [3])
other investigational drug
Item
patients who received any investigational drug other than opc-41061 within 30 days prior to commencement of administration of opc-41061
boolean
C0013230 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
participation not allowed
Item
any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study
boolean
C2348568 (UMLS CUI [1,1])
C0683607 (UMLS CUI [1,2])
C0683607 (UMLS CUI [1,2])